JP2021518137A5 - - Google Patents

Info

Publication number
JP2021518137A5
JP2021518137A5 JP2020550711A JP2020550711A JP2021518137A5 JP 2021518137 A5 JP2021518137 A5 JP 2021518137A5 JP 2020550711 A JP2020550711 A JP 2020550711A JP 2020550711 A JP2020550711 A JP 2020550711A JP 2021518137 A5 JP2021518137 A5 JP 2021518137A5
Authority
JP
Japan
Prior art keywords
acid sequence
amino acid
seq
sequence shown
binding molecule
Prior art date
Application number
JP2020550711A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2019179396A5 (https=
JP2021518137A (ja
JP7482031B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2019/078515 external-priority patent/WO2019179396A1/en
Publication of JP2021518137A publication Critical patent/JP2021518137A/ja
Publication of JPWO2019179396A5 publication Critical patent/JPWO2019179396A5/ja
Publication of JP2021518137A5 publication Critical patent/JP2021518137A5/ja
Priority to JP2024007290A priority Critical patent/JP2024029261A/ja
Application granted granted Critical
Publication of JP7482031B2 publication Critical patent/JP7482031B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020550711A 2018-03-20 2019-03-18 新規の抗ｐｄ－１抗体 Active JP7482031B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024007290A JP2024029261A (ja) 2018-03-20 2024-01-22 新規の抗ｐｄ－１抗体

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN201810255570.3 2018-03-20
CN201810255570 2018-03-20
CN2018079631 2018-03-20
CNPCT/CN2018/079631 2018-03-20
PCT/CN2019/078515 WO2019179396A1 (en) 2018-03-20 2019-03-18 Novel anti-pd-1 antibodies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024007290A Division JP2024029261A (ja) 2018-03-20 2024-01-22 新規の抗ｐｄ－１抗体

Publications (4)

Publication Number Publication Date
JP2021518137A JP2021518137A (ja) 2021-08-02
JPWO2019179396A5 JPWO2019179396A5 (https=) 2022-03-16
JP2021518137A5 true JP2021518137A5 (https=) 2022-03-16
JP7482031B2 JP7482031B2 (ja) 2024-05-13

Family

ID=67986701

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020550711A Active JP7482031B2 (ja) 2018-03-20 2019-03-18 新規の抗ｐｄ－１抗体
JP2024007290A Pending JP2024029261A (ja) 2018-03-20 2024-01-22 新規の抗ｐｄ－１抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024007290A Pending JP2024029261A (ja) 2018-03-20 2024-01-22 新規の抗ｐｄ－１抗体

Country Status (7)

Country Link
US (2) US12030941B2 (https=)
EP (1) EP3768724A4 (https=)
JP (2) JP7482031B2 (https=)
CN (2) CN116333126A (https=)
CA (1) CA3093992A1 (https=)
TW (1) TWI829677B (https=)
WO (1) WO2019179396A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116333126A (zh) * 2018-03-20 2023-06-27 上海药明生物技术有限公司 新型抗pd-1抗体
CN112442122B (zh) * 2019-09-04 2021-09-21 上海洛启生物医药技术有限公司 阻断型pd-1纳米抗体及其编码序列和用途
CN114430746B (zh) * 2019-09-25 2023-09-01 上海药明生物技术有限公司 新型抗pd-l1抗体
WO2021063201A1 (zh) * 2019-09-30 2021-04-08 四川科伦博泰生物医药股份有限公司 抗pd-1抗体及其用途
BR112022023989A2 (pt) 2020-05-26 2023-02-07 Boehringer Ingelheim Int Anticorpos anti-pd-1
CN118240082A (zh) * 2020-12-28 2024-06-25 浙江纳米抗体技术中心有限公司 Pd-1结合分子及其应用
US20240092908A1 (en) * 2020-12-31 2024-03-21 Zhejiang Doer Biologics Co., Ltd. Anti-pd-1 single-domain antibody
WO2022161454A1 (zh) * 2021-01-29 2022-08-04 明慧医药（杭州）有限公司 抗原结合蛋白及其用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2494107C2 (ru) * 2005-05-09 2013-09-27 Оно Фармасьютикал Ко., Лтд. Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами
WO2009114335A2 (en) * 2008-03-12 2009-09-17 Merck & Co., Inc. Pd-1 binding proteins
CN105061597B (zh) * 2015-06-09 2016-04-27 北京东方百泰生物科技有限公司 一种抗pd-1的单克隆抗体及其获得方法
CN106432494B9 (zh) 2015-08-11 2022-02-15 广州誉衡生物科技有限公司 新型抗-pd-1抗体
MA43260A (fr) * 2015-11-18 2018-09-26 Merck Sharp & Dohme Liants pd1 et/ou lag3
CN106046162B (zh) * 2016-06-21 2019-04-02 大庆东竺明生物技术有限公司 抗人程序性死亡因子1（pd-1）单克隆抗体的制备及应用
CN107474135B (zh) * 2017-02-17 2020-08-18 广西医科大学 抗PD-1的纳米抗体PD-1/Nb20及其制备方法与应用
AR114127A1 (es) * 2018-03-02 2020-07-22 Lilly Co Eli Anticuerpos agonistas contra pd-1 y usos de estos
CN116333126A (zh) * 2018-03-20 2023-06-27 上海药明生物技术有限公司 新型抗pd-1抗体

Similar Documents

Publication Publication Date Title
JP2021518137A5 (https=)
CN112457403B (zh) 抗pd1抗体及其作为治疗剂与诊断剂的用途
JP7041516B2 (ja) 共通軽鎖を有する二重特異性抗体又は抗体混合物
JP2022106783A (ja) 抗ｐｖｒｉｇ抗体及び使用方法
CN110431231B (zh) 抗-cd3抗体和包含所述抗体的分子
JP7352973B2 (ja) 二重特異性抗体及びその使用
US11345754B2 (en) Monoclonal antibody antagonizing and inhibiting the binding of human PD-1 antigen to its ligand, preparation method therefor and application thereof
EP4378954A1 (en) Anti-pvrig/anti-tigit bispecific antibody and application
CN112119099A (zh) 三特异性抗原结合蛋白
WO2016197497A1 (zh) 一种抗pd-1的单克隆抗体及其获得方法
CN113508139B (zh) 结合人lag-3的抗体、其制备方法和用途
KR20210131997A (ko) 항-btla 항체
CN116789820A (zh) 一种新型免疫调节剂的开发和应用
EP4458854A1 (en) Gprc5d antibody and application thereof
JP7843824B2 (ja) 抗体および使用方法
CN111094339A (zh) 抗pd-1抗体和抗lag-3抗体联合在制备治疗肿瘤的药物中的用途
EP4389770A1 (en) Bispecific antibody and use thereof
JPWO2019179396A5 (https=)
JP2025532700A (ja) 抗ｃｄ２８抗体
JP2021534750A (ja) 新規ながん免疫療法抗体組成物
CN113368232B (zh) 多特异性抗原结合蛋白及其应用
CN110760517A (zh) 拮抗pd-1骆驼抗体类似物ap基因及蛋白和应用
WO2025195358A1 (zh) Pd-1结合蛋白及医药用途
WO2026059969A1 (en) Human pd-1 and ctla4 neutralizing vhh antibodies and methods of use thereof
JP2025503789A (ja) 抗成長分化因子１５の抗体分子及びその応用